Evidence map›Paper›PMID 40339040›Full record

ArticlePloS one2025

Anti-cancer activity elucidation of geissolosimine as an MDM2-p53 interaction inhibitor: An in-silico study.

Md Al-Amin, Rehnuma Tanjin, Md Rasul Karim, Jannatul Mawa Etee, Ayesha Siddika, Nafisa Akter, Md Helal Uddin, Ratul Mahmud, Tasfia Saffat, Md Faruk Hossen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Md Al-AminDepartment of Pharmacy, Islamic University, Kushtia, Bangladesh.ORCID https://orcid.org/0009-0009-1982-7001
Rehnuma TanjinDepartment of Pharmacy, Islamic University, Kushtia, Bangladesh.
Md Rasul KarimDepartment of Pharmacy, Islamic University, Kushtia, Bangladesh.
Jannatul Mawa EteeDepartment of Pharmacy, Islamic University, Kushtia, Bangladesh.
Ayesha SiddikaDepartment of Pharmacy, Islamic University, Kushtia, Bangladesh.
Nafisa AkterDepartment of Pharmacy, Islamic University, Kushtia, Bangladesh.
Md Helal UddinDepartment of Pharmacy, Islamic University, Kushtia, Bangladesh.
Ratul MahmudDepartment of Pharmacy, Islamic University, Kushtia, Bangladesh.
Tasfia SaffatDepartment of Pharmacy, Islamic University, Kushtia, Bangladesh.
Md Faruk HossenDepartment of Pharmacy, Islamic University, Kushtia, Bangladesh.
Samira Idris MowleeDepartment of Pharmacy, Islamic University, Kushtia, Bangladesh.ORCID https://orcid.org/0009-0001-0342-3231
Elmu Kabir RafaDepartment of Pharmacy, Islamic University, Kushtia, Bangladesh.
Sumi AkterDepartment of Pharmacy, Islamic University, Kushtia, Bangladesh.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For cancer treatment, Inhibition of murine double minute (MDM2) & p53 interaction is considered an attractive therapeutic approach. In this study, we performed an integrated virtual screening (i.e., QSAR, structural similarity, molecular docking, and molecular dynamic simulation) on the in-house building alkaloids library. Geissolosimine (i.e., an indole alkaloid) was predicted as a potential inhibitor for MDM2-p53 interaction. The predicted pIC50 value of Geissolosimine, was 7.013 M. Moreover, Geissolosimine showed 0.62% structural similarity to 'SAR405838' (i.e., a clinical trial inhibitor for MDM2-p53 interaction inhibition); and a docking score of -10.9 kcal/mol that was higher than the 'SAR405838'.100 ns molecular dynamics simulation (MDS) was performed to validate the docking result and it exhibited better binding stability to MDM2. The pharmacokinetic & drug-likeness analysis suggested that Geissolosimine had potential to be a drug-like compound. However, in vitro & in vivo assays will be required to validate this study.

Indexed as

Antineoplastic AgentsIndole AlkaloidsProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53HumansMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingQuantitative Structure-Activity RelationshipAntineoplastic AgentsIndole AlkaloidsMDM2 protein, humanProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53

Identifiers

PMID40339040
PMCPMC12061181

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.